| 2021 | Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma
| ANNALS OF ONCOLOGY |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2001 | Monthly 5-days 5-fluorouracil and low-dose leucovorin for adjuvant chemotherapy in colon cancer | CANCER LETTERS |
| 2022 | MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma-Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2007 | Multi-institutional phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations
| ONCOLOGIST |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2005 | Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
| ANNALS OF ONCOLOGY |
| 2016 | Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
| ONCOTARGET |
| 2017 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2021 | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
| GASTRIC CANCER |
| 2022 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial | LANCET ONCOLOGY |
| 2007 | Novel and simple transformation algorithm for combining microarray data sets
| BMC BIOINFORMATICS |
| 2008 | Novel biomarker candidates for gastric cancer | ONCOLOGY REPORTS |
| 2023 | Novel HER2-targeted therapy to overcome trastuzumab resistance in HER2-amplified gastric cancer
| SCIENTIFIC REPORTS |
| 2009 | Oncogenic pathway combinations predict clinical prognosis in gastric cancer
| PLOS GENETICS |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2020 | Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I | MOLECULAR CANCER THERAPEUTICS |
| 2023 | Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea
| PALLIATIVE MEDICINE REPORTS |
| 2010 | Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 1996 | Overexpression of c-ErbB-2 Protein in Gastric Cancer by Immunohistochemical Stain | ONCOLOGY |
| 2012 | Overexpression of class III beta tubulin and amplified HER2 gene predict good response to paclitaxel and trastuzumab therapy
| PLOS ONE |
| 1996 | P-glycoprotein as an intermediate end point of drug resistance to neoadjuvant chemotherapy in locally advanced gastric cancer
| YONSEI MEDICAL JOURNAL |
| 1997 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer | BIOCHEMICAL PHARMACOLOGY |
| 1998 | p53 유전자 변형이 발생한 위암세포주에서 유전자이상 교정에 의한 항암제 감수성 변화
| Journal of the Korean Cancer Association (대한암학회지) |
| 2010 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2022 | PD-L1 expression and overall survival in Asian and western patients with gastric cancer | FUTURE ONCOLOGY |
| 2020 | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies | JOURNAL OF THORACIC ONCOLOGY |
| 2019 | Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
| Gastric Cancer |
| 2016 | Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | LANCET ONCOLOGY |
| 2018 | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
| CANCER SCIENCE |
| 2023 | Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062
| JAPANESE JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial | LANCET |
| 2018 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial | LANCET |
| 2022 | Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial | JOURNAL OF CLINICAL ONCOLOGY |
| 2008 | Pemetrexed and cisplatin in patients with advanced gastric cancer: a Korean cancer study group multicenter phase II study. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 1995 | Perioperative blood transfusions and prognosis in patients with curatively resected locally advanced gatric cancer | ONCOLOGY |
| 2021 | Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations
| INVESTIGATIONAL NEW DRUGS |
| 2008 | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2014 | Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2008 | Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer
| ANNALS OF ONCOLOGY |
| 2010 | Phase II study of preoperative chemoradiotherapy (CRT) with irinotecan plus S-1 in locally advanced rectal cancer | RADIOTHERAPY AND ONCOLOGY |
| 2011 | Phase II study of sunitinib as second-line treatment for advanced gastric cancer
| INVESTIGATIONAL NEW DRUGS |
| 2019 | Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer | RADIOTHERAPY AND ONCOLOGY |
| 2008 | Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
| ANNALS OF ONCOLOGY |
| 1998 | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2015 | PINCH-2 presents functional copy number variation and suppresses migration of colon cancer cells by paracrine activity | INTERNATIONAL JOURNAL OF CANCER |
| 2009 | Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2009 | Prediction of high-risk patients by genome-wide copy number alterations from remaining cancer after neoadjuvant chemotherapy and surgery. | INTERNATIONAL JOURNAL OF ONCOLOGY |
| 2013 | Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer
| BMC CANCER |
| 2009 | Prediction of recurrence of early gastric cancer after curative resection | ANNALS OF SURGICAL ONCOLOGY |
| 2009 | Prediction of S-1-induced anemia | GASTRIC CANCER |
| 2011 | Predictive values of 5-fluorouracil pathway genes for S-1 treatment in patients with advanced gastric cancer | ANTI-CANCER DRUGS |
| 2011 | Prevalence and associated factors of psychological distress among Korean cancer patients | GENERAL HOSPITAL PSYCHIATRY |
| 2017 | Prevalence and prognostic implications of psychological distress in patients with gastric cancer
| BMC CANCER |
| 1995 | Primary lymphoma of thyroid
| YONSEI MEDICAL JOURNAL |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2022 | Probe-Based Confocal Laser Endomicroscopy versus White-Light Endoscopy with Narrow-Band Imaging for Predicting and Collecting Residual Cancer Tissue in Patients with Gastric Cancer Receiving Chemotherapy
| CANCERS |
| 2009 | Prognosis of pN3 stage gastric cancer
| CANCER RESEARCH AND TREATMENT |
